Breast cancer is a common cancer in women with high mortality. With advances in diagnostic techniques and the application of new treatments, such as targeted therapy for HER2 amplification, the systemic disease control rate has been improved and the overall survival rate has been extended, while brain metastases are increasingly more common. Symptomatic brain metastases account for 10% to 16% of all patients with breast cancer, and the patients with brain metastases confirmed by autopsy account for about 30% [1 4] . Brain metastases from breast cancer result in high mortality and have become a major factor leading to the decline in survival. There are different subtypes of breast cancer, and research suggests that simultaneous negative expressions of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), and HER2 overexpression are risk factors for brain metastases occurring in patients with breast cancer [511] . Wholebrain radiotherapy (WBRT), surgery, stereotactic radiosurgery (SRS), chemotherapy, and targeted therapy are the common treatments for brain metastases from breast cancer. The purpose of this study was to analyze the clinicopathologic characteristics of different subtypes of patients with breast cancer with brain metastases and prognostic factors, to provide a reference to improve the prevention and treatment of brain metastases from breast cancer.
Breast cancer is a common cancer in women with high mortality. With advances in diagnostic techniques and the application of new treatments, such as targeted therapy for HER2 amplification, the systemic disease control rate has been improved and the overall survival rate has been extended, while brain metastases are increasingly more common. Symptomatic brain metastases account for 10% to 16% of all patients with breast cancer, and the patients with brain metastases confirmed by autopsy account for about 30% [1 4] . Brain metastases from breast cancer result in high mortality and have become a major factor leading to the decline in survival. There are different subtypes of breast cancer, and research suggests that simultaneous negative expressions of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), and HER2 overexpression are risk factors for brain metastases occurring in patients with breast cancer [511] . Wholebrain radiotherapy (WBRT), surgery, stereotactic radiosurgery (SRS), chemotherapy, and targeted therapy are the common treatments for brain metastases from breast cancer. The purpose of this study was to analyze the clinicopathologic characteristics of different subtypes of patients with breast cancer with brain metastases and prognostic factors, to provide a reference to improve the prevention and treatment of brain metastases from breast cancer.
窑 Clinical Research窑
The clinical data of 89 patients with brain metastases from breast cancer treated at Sun Yatsen University Cancer Center between October 1997 and July 2008 were collected, including the performance status, pathologic diagnosis, tumor stage, treatment, the time and location of metastases, as well as the ER, PR, and HER2 status. All patients were women and the median age at first visit was 44 years (2667 years). Of these patients, 73.0% (65) had not reached menopause. Regarding pathologic type, 87.6% (78 patients) had invasive ductal carcinoma, 2.3% (2 patients) had invasive lobular carcinoma, and 10.1% (9 patients) had an unknown pathologic type. The histologic grade for 89.9% (80 patients) was grade II or III. In 12 patients with newly diagnosed stageIV disease, 9 patients had multiple metastases, including to bone or visceral organs, 2 had brain metastases, and 1 had distant lymph node metastases alone.
All patients had pathologic diagnoses of primary tumors and were staged by the 7th edition of the American Joint Committee on Cancer (AJCC) breast cancer tumor node metastasis (TNM) staging system. HER2 gene overexpression was defined as +++ by immunohistochemistry, or + by fluorescence in situ hybridization (FISH), or + by chromogenic in situ hybridization (CISH). According to immunohistochemical indicators, patients with breast cancer were divided into four subtypes: luminal type A was defined as ERpositive or PRpositive and HER2negative; luminal type B was defined as ERpositive or PRpositive and HER2positive; the HER2 overexpression type was defined as ER and PRnegative and HER2positive; and triplenegative (TN) breast cancer was defined as ER, PR, and HER2negative. Because the immunohistochemical results of 9 patients were unknown, 80 patients with immunohistochemical results were classified based on the above definition, including 37.5% (30 patients) with luminal type A , 25.0% (20 patients) with luminal type B, 20.0% (16 patients) with HER2 overexpression, and 17.5% (14 patients) with TN. Brain metastasis was diagnosed by clinical symptoms, signs, and cranial magnetic resonance imaging (MRI) or computer tomography (CT).
In the 89 patients, 12 patients with newly diagnosed stageIV disease received chemotherapy containing anthracycline and taxane as firstline treatment, of whom 5 patients received palliative breast resection and 6 patients received radiotherapy. All 89 patients with brain metastases were women, accounting for 11.4% of 780 patients with recurrent or metastatic breast cancer in the same period. The median diseasefree interval from the first consultation to the first recurrence or metastasis was 20.0 months (0127.0 months). The most common site of first recurrence or metastasis was bone (43 patients, 48.3% ), followed by lung or pleura (41 patients, 46.1% ), and brain (25 patients, 28.1% ). The median time from the first diagnosis to the diagnosed brain metastases was 30.0 months (0128.0 months). In addition to 2 patients with newly diagnosed brain metastases, brain metastases in 9 patients (10.3% ) with newly diagnosed stageI disease developed at a median time of 66.5 months (95% CI: 33.01131.21 months), for 36 patients (41.4% ) with stageII disease the median time was 34.0 months (95% CI: 31.3851.23 months), for 32 patients (36.8%) with stageIII disease the median time was 34.0 months (95% CI: 29.4055.42 months), and for 10 patients (11.5%) with stageIV disease the median time was 10.0 months (95% CI: 6.4916.11 months) ( < 0.001). The median age to be diagnosed with brain metastases was 46 years (2874 years), with a median performance status score of 1 point (0 to 3 points). Regarding first, second, third, and fourth recurrence, 25.8% (23 patients), 42.7% (38 patients), 15.7% (14 patients), and 13.5% (12 patients) had brain metastases, respectively. The most common site of accompanied metastases after the diagnosis of brain metastases was lung or pleura (57 patients, 64.1%), followed by bone (55 patients, 61.8%). Other metastatic sites included local or distant lymph nodes (43 patients, 48.3% ), liver (34 patients, 38.2%), local recurrence (28 patients, 31.5%), skin or soft tissue (18 patients, 20.2% ), contralateral breast (10 patients, 11.2%), and other sites (4 patients, 4.5%). Age at first diagnosis, time from first diagnosis to brain metastases, and time to progression after firstline treatment in different patient subtypes showed significant differences (Table 1 ).
All patients were followed until July 31, 2009, with a median followup of 41.0 months (6.0141.0 months). At the followup cutoff, 83.2% (74 patients) had died, 14.6% (13 patients) survived, and 2 patients were lost to followup. The median survival time of patients with brain metastases was 8.0 months (080.0 months, 95% CI: 6.579.42 months), the 1year survival rate was 32%, the 2year survival rate was 17% , and the 5year survival rate was 4% (Figure 1) . The overall survival time in patients with luminal type A showed significant differences with other subtypes (Figure 2 ), but the survival time after brain metastases in the various subtypes showed no significant differences (Table 1) . These indicated that patients with HER2 overexpression and TN had rapid disease progression, short times of effective treatment, and short overall survival time, with poor prognosis particularly in patients with HER2 overexpression. Univariate analysis showed that performance status score, time to brain metastases, time from the first consultation to brain metastases, number of brain metastases, extracranial metastasis, treatment of brain metastases, endocrine therapy, and chemotherapy using taxane and capecitabine all had an impact on survival. The analysis of age and different subtypes indicated that patients younger than 55 years and patients with luminal type A disease had a tendency for good prognosis, but without statistical significance.
Multivariate analysis showed that performance status score, number of brain metastases, and the treatment of brain metastases with or without endocrine therapy had an impact on survival. Patients with performance status scores of 0 to 1 points, with single brain metastasis, receiving WBRT combined with Figure 2 Overall survival of patients with different subtypes of breast cancer Figure 1 Overall survival of all patients chemotherapy, and receiving endocrine therapy had a better prognosis (Table 2) .
Endocrine therapy had great significance in patients with positive hormone receptors. In this study the treatment and prognosis of patients with luminal types (including type A and type B) were analyzed separately. In patients with luminal types of breast cancer with brain metastases, those with performance status scores of 0 to 1 points had a better prognosis, and radiotherapy and tamoxifen could improve survival. Patients with single metastasis and receiving chemotherapy had a tendency of good prognosis, and aromatase inhibitor therapy had no significant effect on survival (Table 3 ).
In this study 30 patients with previous adjuvant tamoxifen therapy were further analyzed. The median time of adjuvant tamoxifen therapy in 30 patients was 25 months (260 months), of which 25 patients also received sequential therapy with aromatase inhibitors. A total of 14 patients had recurrence or metastasis during adjuvant endocrine therapy and the median time to progression was 18 months (254 months). A total of 16 patients had recurrence or metastasis after the cessation of adjuvant endocrine therapy, and the median time from the cessation to recurrence or metastasis was 15 months (250 months). After the occurrence of brain metastases, the patients that received tamoxifen treatment had an obviously longer median survival time compared with those that did not receive tamoxifen (25 months vs. 6 months). Multivariate analysis showed that endocrine therapy was an independent prognostic factor ( Figure 3 ). This indicate that in patients with luminal types of disease that received previous adjuvant tamoxifen therapy, the continued use of tamoxifen still had a survival benefit (Table 4 ).
In 2000, breast cancer was divided into 5 subtypes by Perou .
[12] through cDNA microarray technology: luminal A, luminal B, HER2 overexpressing, basallike, and normal breast like, and different subtypes had significant differences in prognosis . Because genotyping needs fresh specimens and high technology, it cannot be used in clinic routinely, and immunohistochemistry is often clinically used for typing. A large body of research suggests that HER2 gene overexpression increases proliferation, survival, antiapoptosis, migration, and invasive capabilities of tumor cells and is an important risk factor for brain metastases from breast cancer [811] . TN breast cancer is characterized by a high rate of early recurrence, rapid progression, a high rate of visceral metastasis, and easy metastasis of the central nervous system [57] . The results of this study also showed that patients with HER2 overexpression and TN breast cancer had poor prognosis, early brain metastases, and rapid disease progression after treatment.
In this study, performance status scores, number of metastases, and treatment were independent prognostic factors for patients with breastcancer related brain metastasis. Performance status score is a prognostic factor for many tumors reflecting the overall survival of patients, and is an important reference for assessing patients and clinical decisionmaking. Multiple metastases indicate a high proliferation rate and strong invasions of tumor cells, or a weak antitumor immunity of the body. Compared with multiple metastases, a single metastasis has more of a chance to be cured through further surgery or stereotactic radiotherapy.
This study showed that age and accompanied metastases had no significant effect on the prognosis. In general, age is an important prognostic factor in patients with breast cancer. In newly diagnosed patients, being younger than 35 years is a high risk factor for breast cancer recurrence. But in patients with brain metastases from breast cancer, the young do not necessarily represent short survival time. Some studies suggested that age was not an independent prognostic factor in patients with breast cancer metastasis [5, 6] . This study also found no survival differences among patients of different ages, but patients younger than 55 years had a better trend. The reason may be that older patients have poorer physical condition and immune function, often with hypertension, diabetes, and other chronic diseases, so the performance status is relatively poor, which to some extent affects prognosis. In patients accompanied with extracranial metastasis, some research reported that patients with visceral metastasis had poor prognosis [2, 13] . However, in this study, the corresponding multivariate analysis showed no statistical significance.
The main treatments for brain metastases from breast cancer include WBRT, chemotherapy, endocrine therapy, targeted therapy, surgery, SRS, and so on. This study showed that on the whole, WBRT combined with systemic chemotherapy had the best results ( < 0.001). In the past 50 years, WRBT has been considered the standard treatment for brain metastases. It can delay or prevent the progress of nerve damage, relieve symptoms, and improve patient qualityoflife. The local control rate with WBRT can be up to 90% 100%. The role of chemotherapy is still controversial and its limitations currently include the following. First, only a few drugs can enter the brain because of the bloodbrain barrier. Secondly, Pglycoprotein is highly expressed in brain capillary endothelial cells, which can transport chemotherapy drugs with various structures and functions out of the cells [14] . Finally, drugs that can get through the bloodbrain barrier are often not sensitive to the tumors, or have been used in previous treatment, so the tumors have become resistant. Currently, the benefit of chemotherapy combined with radiotherapy is considered because the bloodbrain barrier is destroyed after radiotherapy so drugs can get into the brain more easily, and systemic chemotherapy is an effective means to control other lesions. In chemotherapy drugs, capecitabine has been a research hotspot in recent years [1518] , but in this study it was not found to improve survival.
Because of the small number of patients, targeted therapy, SRS, and surgery were not analyzed in this study, and these methods also have some effect in specific patients. It is reported that the smallmolecule tyrosine kinase inhibitor lapatinib has good therapeutic effect in patients with HER2 positive breast cancer with brain metastases [19, 20] . The median survival time of patients with breastcancer related brain metastases treated by SRS can be up to 10.513 months [21, 22] , and in the present study 1 patient received 酌 knife treatment and achieved the longest survival time in the whole group (80 months).
Endocrine therapy is currently considered to have a slow onset and is not the first choice in patients with brain metastases from breast cancer. In commonly used drugs, tamoxifen can pass through the bloodbrain barrier and has a certain effect in patients with brain metastasis from breast cancer [23] . Aromatase inhibitors play an antitumor effect through further reducing the estrogen level in postmenopausal patients, but have no direct effect on tumor cells. Some research has reported that letrozole displayed a certain degree of activity in treatment [24] . The new antiestrogen drug fulvestrant was found not to pass through bloodbrain barrier in earlier studies. It is interesting that the results of this study showed that tamoxifen could improve the prognosis of patients with brain metastases from luminaltype breast cancer, regardless of whether adjuvant therapy with tamoxifen was used. However, these conclusions have certain limitations because of the small number of patients and the retrospective analysis. In clinical work, after the diagnosis of brain metastases, patients first receive WBRT and systemic chemotherapy, followed by endocrine therapy. After 25 months of chemotherapy and radiotherapy, treatmentsensitive patients have a reduction or disappearance of tumor lesions and improved performance status and can receive further treatment, while the patients not sensitive to treatment often deteriorate rapidly. Therefore, the patients accepting tamoxifen usually have good performance status and are sensitive to previous treatment. Those who do not receive tamoxifen usually have disease that cannot be controlled by radiotherapy or chemotherapy and die before tamoxifen therapy, which may be a bias factor. In addition, in this study, nearly half of the patients (14) had progression with endocrine therapy. Clinically, disease progression in patients after palliative treatment is not uncommon. Can patients still benefit from tamoxifen after progression? On the other hand, taking into account the priority of endocrine therapy, can patients with negative hormone receptor disease (including TN and HER2) also benefit from tamoxifen therapy? Prospective study is needed to observe the efficacy of tamoxifen. At present it has been confirmed that preventive WBRT can improve the overall survival rate of patients with smallcell lung cancer after complete remission by chemotherapy [25] . In clinic, preventive intrathecal injection has become a common treatment in patients at high risk for lymphoma and leukemia. For those patients with breast cancer with a high risk of brain metastases, learning from the treatment experience of smallcell lung cancer and lymphoma, whether preventive radiotherapy and intrathecal injection can be used to prevent or delay the occurrence of brain metastases and improve overall survival remains to be further studied.
In summary, patients with brain metastases from breast cancer have short survival times, and patients with the HER2 and TN types have particularly poor prognosis. Specific multidisciplinary treatments should be taken depending on the specific circumstances of patients with breastcancer related brain metastases. WBRT combined with chemotherapy is the appropriate treatment, and in patients with positive hormone receptors, tamoxifen therapy can prolong survival. Targeted therapy, SRS, and surgery also have a certain role for specific patients. Prospective randomized controlled studies can help to further understand the risk factors, prognostic factors, and treatments for patients with breast cancer brain metastasis. In patients at high risk for brain metastases, whether routine brain screening should be used regularly and whether preventive treatment should be used to prevent or delay the occurrence of brain metastases and improve overall survival still needs further study.
